Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization Osaka, Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan.
Clin Lung Cancer. 2013 Jan;14(1):50-4. doi: 10.1016/j.cllc.2012.03.012. Epub 2012 May 18.
Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of bone matrix.
We measured serum NTx levels in patients who underwent staging during hospitalization for the initial treatment of lung cancer in our department. We examined whether serum NTx levels would be relevant to the prognosis of non-small-cell lung cancer (NSCLC).
This study included 176 patients with lung cancer (125 men and 51 women), including 109 with adenocarcinoma, 53 with squamous cell carcinoma, 6 with large-cell carcinoma, and 8 with other cancer types. Univariate and multivariate analysis using the Cox proportional hazards model revealed a particularly close association between sex, performance status, disease stage, and serum NTx levels and overall survival (OS). A median OS of 368 days was observed for patients with a serum NTx level < 22 nmol BCE/L, which was significantly longer than the 197 days for patients with a serum NTx level ≥ 22 nmol BCE/L (hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.36-2.99; log-rank P = .00037).
We have revealed that a high serum NTx level (> 22 nmol BCE/L) appears to be a risk factor for a reduction in OS in patients with NSCLC.
肺癌是癌症相关死亡的主要原因。许多肺癌患者在诊断时已处于晚期。肺癌的 5 年生存率为 10%至 20%，肺癌患者的预后仍然较差。I 型胶原交联 N-末端肽（NTx）是 I 型胶原的代谢产物，是骨基质的主要成分。
我们测量了在我院住院接受初始肺癌治疗分期的患者的血清 NTx 水平。我们研究了血清 NTx 水平是否与非小细胞肺癌（NSCLC）的预后相关。
这项研究包括 176 名肺癌患者（125 名男性和 51 名女性），其中 109 名患有腺癌，53 名患有鳞状细胞癌，6 名患有大细胞癌，8 名患有其他癌症类型。使用 Cox 比例风险模型进行的单因素和多因素分析显示，性别、表现状态、疾病分期和血清 NTx 水平与总生存期（OS）之间存在特别密切的关系。血清 NTx 水平<22 nmol BCE/L 的患者中位 OS 为 368 天，明显长于血清 NTx 水平≥22 nmol BCE/L 的患者的 197 天（风险比[HR]，2.02；95%置信区间[CI]，1.36-2.99；对数秩 P=0.00037）。
我们发现，高血清 NTx 水平（>22 nmol BCE/L）似乎是 NSCLC 患者 OS 降低的一个危险因素。
